Cipla enters the respiratory market in Germany and Sweden with affordable high quality alternatives

Cipla has launched Serroflo, its Salmeterol/Fluticasone MDI, in Germany and Sweden. With this launch, Cipla opens the door for new, highly efficient treatments in the European healthcare market. Serroflo will substantially improve the affordability of fixed combinations in Europe and help manage health costs for respiratory treatment.

"With Serroflo, we offer in Germany and Sweden an alternative that is effective and efficient and, therefore, brings many advantages into a market that suffers from limited resources", said Mr Frank Pieters, head of Cipla Europe.

In Germany, the new product is distributed under the name 'Serroflo', whereas in Sweden the combination is launched as 'Salmeterol/Fluticasone Cipla'. Serroflo and Salmeterol/Fluticasone Cipla will be available in a pMDI with HFA propellant in two strengths:  

1.    120 doses of 25/125 mcg salmeterol/fluticasone

2.    120 doses of 25/250 mcg salmeterol/fluticasone

Apart from Croatia, where the combination is already available under the name Duohal, Germany and Sweden are amongst the first markets where Cipla is active and others will follow. "Over the next 12–18 months we will see a series of launches throughout Europe as we know that there is a common need for high quality, affordable, reliable and thus sustainable therapy-alternatives — and this is what Cipla stands for," said Mr Subhanu Saxena, managing director and Global CEO of Cipla.